Innovative therapeutics

Investors

IR Snapshot

NASDAQBMRN
Beta1.84
Shares Outstanding175.3M
Average Volume (10 days)1.4M
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($1.00)
Sales (TTM)$6.85
Book Value (MRQ)$15.95
Cash Flow (TTM)($0.42)
Cash (MRQ)$4.17

Analyst Views

Current Mean RecommendationStrong Buy
Strong Buy14
 
Buy2
 
Hold4
 
Underperform0
 
Sell0
 

Recent Insider Transactions

G. Eric Davis
EVP, General Counsel
(9,844)
Sell
Jun 23, 2017
Brian Mueller
SVP, Corporate Controller
(2,671)
Sell
Jun 22, 2017
Henry J. Fuchs
President, Worldwide R&D
(603)
Sell
Jun 19, 2017
V. Bryan Lawlis
(3,750)
Sell
Jun 16, 2017
Henry J. Fuchs
President, Worldwide R&D
(5,000)
Sell
Jun 16, 2017

Recent SEC Filings

Insider Buy/Sell
Sep 19, 2017
Insider Buy/Sell
Sep 19, 2017
Company Events
Aug 11, 2017
Prospectus
Aug 9, 2017
FWP
Aug 9, 2017

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information